In a small group of 10 people with Graves' disease who received radioactive iodine, none experienced a worsening of their eye symptoms over a year, but this result is too limited to conclude that radioactive iodine is safe for the eyes in all patients.
Claim Context
Among patients with Graves' disease treated with radioactive iodine, no worsening of Graves' ophthalmopathy was observed in a cohort of 10 patients over 12 months, but this finding cannot be generalized due to the small sample size and lack of control group.
“No worsening of Graves’ ophthalmopathy (GO) was observed during the study period. One subject with severe inactive GO at baseline showed no deterioration of ophthalmic symptoms throughout the 12-month evaluation.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The pooled risk of new-onset or worsening Graves' ophthalmopathy following RAI therapy compared to anti-thyroid drugs or thyroidectomy in patients with pre-existing or active eye disease.
A systematic review and meta-analysis of prospective cohort studies and RCTs comparing RAI to ATD or surgery in Graves' disease patients with baseline ophthalmopathy, reporting incidence of GO worsening at 6, 12, and 24 months, with standardized grading (e.g., EUGOGO criteria), including at least 5000 patients across 30+ studies.
Whether RAI increases the risk of worsening Graves' ophthalmopathy compared to ATD in patients with mild to moderate eye disease.
A double-blind RCT of 300 adults with Graves' disease and mild-to-moderate ophthalmopathy (EUGOGO grade 1–3), randomized to RAI (10–15 mCi) or ATD (methimazole) for 12 months, with primary outcome of GO worsening (≥2-point increase in clinical activity score) at 12 months, with mandatory corticosteroid prophylaxis in both arms.
The incidence of Graves' ophthalmopathy worsening after RAI in a real-world population of patients with pre-existing eye disease.
A prospective cohort study of 500 adults with Graves' disease and baseline ophthalmopathy, treated with RAI (fixed 10–15 mCi), with serial ophthalmologic assessments (EUGOGO score, proptosis, diplopia) at 3, 6, 12, and 24 months, and adjustment for smoking, TRAb, and corticosteroid use.
The prevalence of ophthalmopathy at a single time point after RAI in patients with Graves' disease.
A cross-sectional survey of 500 adults with Graves' disease who received RAI at least 12 months prior, assessing current ophthalmopathy status via standardized clinical exam and imaging, and collecting retrospective treatment history.
Anecdotal reports of ophthalmopathy worsening after RAI in individual patients.
A case series of 10–20 patients with Graves' disease who developed worsening ophthalmopathy after RAI, documenting timing, severity, and management, including baseline and post-RAI EUGOGO scores.